Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Staar Surgical ( (STAA) ).
On February 4, 2026, STAAR Surgical Company entered into a letter agreement with Chief Legal Officer and Corporate Secretary Nathaniel Sisitsky providing for his termination of employment, which is being treated as a termination without cause, effective that same date. Concurrently, the company entered into a consulting agreement under which Sisitsky will provide transition-related legal consulting services through March 13, 2026, in exchange for weekly consulting fees and a potential completion fee. Under the terms aligned with his existing severance agreement, Sisitsky is eligible to receive 12 months of base salary and continued benefits coverage, subject to a general release, as well as his 2025 annual bonus and a remaining $75,000 cash recognition and retention award installment. Restricted stock units scheduled to vest in March 2026 were accelerated and vested as of his separation, while his other unvested equity awards and options were forfeited, signaling a managed leadership transition in the legal function with defined financial and equity arrangements for the departing executive.
The most recent analyst rating on (STAA) stock is a Sell with a $20.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
Spark’s Take on STAA Stock
According to Spark, TipRanks’ AI Analyst, STAA is a Neutral.
The score is primarily held down by poor financial performance (large losses and negative operating cash flow) and a bearish technical setup (below key moving averages with negative MACD). Valuation provides limited support given the negative P/E and no dividend, while corporate events are mixed with improved governance but heightened strategic uncertainty after the terminated merger.
To see Spark’s full report on STAA stock, click here.
More about Staar Surgical
STAAR Surgical Company operates in the medical device industry, focusing on implantable lenses and related ophthalmic products used in vision correction procedures. The company targets the global eye care market, working with ophthalmic surgeons and healthcare providers to offer alternatives to traditional vision correction methods.
Average Trading Volume: 1,364,339
Technical Sentiment Signal: Strong Sell
Current Market Cap: $872.5M
For a thorough assessment of STAA stock, go to TipRanks’ Stock Analysis page.